ALKERMES | ALKS - Stock


ALKERMES reported $298.96M in Stock for its fiscal quarter ending in June of 2026.





Stock Change Date
AbbVie USD 5.13B 78M Jun/2026
Acadia Pharmaceuticals USD 108.67M 77.1M Jun/2026
ALKERMES USD 298.96M 37.75M Jun/2026
Amgen USD 6.22B 34M Jun/2026
Biogen USD 2.22B 159.9M Sep/2026
BioMarin Pharmaceutical USD 1.78B 509.3M Jun/2026
Bristol-Myers Squibb USD 2.74B 19M Jun/2026
Coherus Biosciences USD 5.67M 842K Jun/2026
Eli Lilly USD 16.79B 2.26B Jun/2026
Gilead Sciences USD 1.95B 39M Jun/2026
Heron Therapeutics USD 54.57M 2.33M Dec/2022
Ionis Pharmaceuticals USD 50.83M 45.28M Jun/2026
J&J USD 15.38B 233M Sep/2026
Merck USD 6.21B 272M Jun/2026
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Neurocrine Biosciences USD 104.2M 39.7M Jun/2026
Otsuka Holdings JPY 374.32B 23.79B Dec/2025
Pfizer USD 9.94B 722M Jun/2026
Regeneron Pharmaceuticals USD 3.08B 19.3M Jun/2026
Vertex Pharmaceuticals USD 1.77B 1.6M Jun/2026